Psychedelics like psilocybin and ibogaine are entering mainstream medical research for treating depression, PTSD, and chronic painâconditions affecting millions globally. Governments and pharmaceutical companies face growing pressure to fund this research, while others argue resources should focus on proven treatments. This debate will shape mental health policy worldwide for years to come.